Canton Strategic Holdings (CNTN) Equity Average (2021 - 2026)
Canton Strategic Holdings (CNTN) reported Equity Average of $433.9 million for Q1 2026, up 175919.52% on a YoY basis from N/an in Q1 2025, and up 114.74% quarter-over-quarter from $202.0 million in Q4 2025.
Canton Strategic Holdings (CNTN) Equity Average (2021 - 2026) Analysis & Trends
Canton Strategic Holdings has reported Equity Average for 6 years, with the latest figure at $433.9 million in Q1 2026.
- For the quarter ending Q1 2026, Equity Average rose 175919.52% year-over-year to $433.9 million; the trailing twelve-month figure through Mar 2026 stood at $433.9 million (up 175919.52% YoY), and the FY2025 full-year result was $199.6 million, up 3724.45% from the prior year.
- Equity Average for Q1 2026 stood at $433.9 million, up from $202.0 million in the prior quarter.
- The five-year high for Equity Average was $433.9 million in Q1 2026, with the low at -$223656.0 in Q2 2025.
- Historically, Equity Average has averaged $41.4 million across 5 years, with a median of $4.9 million in 2024.
- Annual changes were most pronounced in 2025 — Equity Average tumbled 103.25% — and 2026, when it jumped 175919.52%.
- Canton Strategic Holdings' Equity Average stood at $6.3 million in 2022, then dropped by 13.99% to $5.4 million in 2023, then sank by 60.28% to $2.2 million in 2024, then soared by 9242.49% to $202.0 million in 2025, then surged by 114.74% to $433.9 million in 2026.
- The last three Equity Average figures came in at $433.9 million (Q1 2026), $202.0 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | 433.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 433.86 Mn |
| Dec 31, 2025 | 202.04 Mn |
| Sep 30, 2025 | 3.26 Mn |
| Jun 30, 2025 | -223,656.00 |
| Mar 31, 2025 | 246,485.50 |
| Dec 31, 2024 | 2.16 Mn |
| Sep 30, 2024 | 4.86 Mn |
| Jun 30, 2024 | 6.87 Mn |
| Mar 31, 2024 | 8.09 Mn |
| Dec 31, 2023 | 5.44 Mn |
| Sep 30, 2023 | 2.41 Mn |
| Jun 30, 2023 | 3.13 Mn |
| Mar 31, 2023 | 4.37 Mn |
| Dec 31, 2022 | 6.33 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 9.69 Mn |
| Mar 31, 2022 | 2.83 Mn |
| Dec 31, 2021 | -5.91 Mn |
| Sep 30, 2021 | -6.72 Mn |
| Jun 30, 2021 | -5.79 Mn |